Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study

Chun, Byoung Chul; Song, Joon Young; Kim, Hyo Youl; Bae, In-Gyu; Kim, Dong-Min; Choi, Young Hwa; Jun, Yoon Hee; Choi, Won Suk; Kang, Seong Hee; Kwon, Hyun Hee; Jeong, Hye Won; Kee, Sae Yoon; Hur, Jun; Chung, Jin-Ho; Yoon, Young Kyung; Yang, Kyung Sook

doi:10.1016/j.vaccine.2019.04.017

Cited by 41 publications

(54 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For PPV23 we identified one cohort study from Germany [20], one TND study from Japan [21], one indirect cohort study from United Kingdom (UK) [22] and three case-control studies from Spain [23], Japan [24] and South Korea [25], respectively ( Table 1). The German cohort study included almost 739,000 inhabitants aged ≥60 years, retrospectively, using routine insurance data collected between 2010 and 2011.…”

Section: Polysaccharide Vaccinementioning

confidence: 99%

“…In South Korea 148 IPD and 557 non-bacteremic pneumococcal pneumonias (NBPP) patients were matched to 295 and 557 hospital controls, respectively. The Korean study identified NBPP cases using sputum culture or urinary antigen test [25].…”

Section: Polysaccharide Vaccinementioning

confidence: 99%

“…VE of the PPV23 vaccine was reported on the following outcomes: all-cause pneumonia [20], CAP [23,24], non-bacteremic pneumococcal pneumonia (NBPP) [25], VT-NBPP [25], pneumococcal pneumonia [21] and VT-pneumonia [21], IPD [25] and VT-IPD [22,25] (Table 1).…”

Section: Polysaccharide Vaccinementioning

confidence: 99%

“…Five studies on PPV23 [20][21][22][23]25] reported VE stratified by age groups (Table 3). For PPV23 there seems to be a decreasing VE with increasing age, and only one study [22] reported a significant VE in the oldest age group (≥85 years).…”

Section: Agementioning

confidence: 99%

“…No other systematic reviews have reported on the VE on VT-pneumonia. In our review we found two recent studies on this topic, a TND study from Japan [21], and a case-control study from South Korea [25]. Both studies evaluated VE of PPV23 in an elderly Asiatic population.…”

Section: Evidence Base For Ppv23mentioning

confidence: 99%

See 4 more Smart Citations

A Systematic Review of Studies Published between 2016 and 2019 on the Effectiveness and Efficacy of Pneumococcal Vaccination on Pneumonia and Invasive Pneumococcal Disease in an Elderly Population

et al. 2020

View full text Add to dashboard Cite

Adult vaccination is high on the agenda in many countries. Two different vaccines are available for the prevention of pneumococcal disease in adults: a 23-valent polysaccharide vaccine (PPV23), and a 13-valent conjugated vaccine (PCV13). The objective of this review is to update the evidence base for vaccine efficacy and effectiveness of PPV23 and PCV13 against invasive pneumococcal disease and pneumonia among an unselected elderly population. We systematically searched for clinical trials and observational studies published between January 1 2016 and April 17 2019 in Pubmed, Embase, Cinahl, Web of Science, Epistemonikos and Cochrane databases. Risk of bias was assessed using Cochrane Risk of Bias tool for and the Newcastle–Ottawa Scale. Results were stratified by vaccine type and outcome. We identified nine studies on PCV13 and six on PPV23. No new randomized clinical trials were identified. Due to different outcomes, it was not possible to do a meta-analysis. New high-quality observational studies indicate protective vaccine effectiveness for both vaccines against vaccine type pneumonia. Our estimates for the protective vaccine efficacy and effectiveness (VE) of PPV23 on pneumonia and pneumococcal pneumonia overlap with results from previously published reviews. Some of the results indicate that the effectiveness of the PPV23 is best in younger age groups, and that it decreases over time.

show abstract